Evidence map›Paper›PMID 41669545›Full record

ArticleFrontiers in endocrinology2026

The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors.

Katarzyna Jóźwik-Plebanek, Marek Saracyn, Adam Daniel Durma, Maciej Kołodziej, Weronika Mądra, Mirosław Dziuk, Katarzyna Janiak, Zuzanna Balcerska, Katarzyna Gniadek-Olejniczak, Grzegorz Kamiński

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katarzyna Jóźwik-PlebanekDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Marek SaracynDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Adam Daniel DurmaDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Maciej KołodziejDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Weronika MądraDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Mirosław DziukNuclear Medicine Department, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Katarzyna JaniakDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Zuzanna BalcerskaDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Katarzyna Gniadek-OlejniczakNeurorehabilitation Clinic, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Grzegorz KamińskiDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Evidence on the efficacy and safety of radioligand therapy (RLT) in lung neuroendocrine tumors (LNETs) remains scarce. The limited data available, derived mainly from retrospective analyses are based on small patient cohorts and heterogeneous treatment protocols. The objective of this study was to assess the efficacy and safety of RLT in patients with SSTR-positive LNETs treated with either [¹ Methods: We conducted a retrospective analysis of 22 LNET patients who received RLT and had complete follow-up data. Treatment response and survival outcomes were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Prognostic associations with PFS and OS were explored using univariate and multivariable Cox proportional hazards models, treatment-related AE were graded according to CTCAE. Results: A total of 22 patients with LNETs (Med. 61 years; 68.2% male) were included. Histology comprised 31.8% typical carcinoid, 54.5% atypical carcinoid, and 13.6% LNET G3. 14 patients received [¹ Conclusions: RLT demonstrated signals of clinically meaningful activity and an acceptable safety profile in patients with advanced LNETs in this small retrospective cohort. Outcomes were numerically more favorable in individuals with high SSTR uptake and in those treated with tandem therapy, but the study was not designed to compare treatment regimens. These exploratory findings should be regarded as hypothesis-generating only and do not provide evidence of comparative efficacy.

Indexed as

Lung NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeOctreotideOrganometallic CompoundsRadiopharmaceuticals177-Lu90-Ylung neuroendocrine neoplasmslung neuroendocrine tumorsNENNEToutcomesRLT

Identifiers

PMID41669545
PMCPMC12883361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.